
Rocket Pharmaceuticals' price target cut to $2.95 amid gene therapy progress and new funding.
Jefferies analyst Andrew Tsai lowered Rocket Pharmaceuticals' price target to $2.95, with shares trading at $2.48. The company is advancing its gene therapy for Danon disease, RP-A501, with an FDA-aligned pivotal study plan. Rocket secured $35 millio...





